Cristiana Caliceti

Prof. Cristiana Caliceti

Dept. of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Emilia-Romagna, Italy
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2017 in Nutrients
Verified
Journal Article
Open access
PDF file
Cristiana CalicetiCristiana Caliceti
Cristiana Caliceti
Donato CalabriaDonato Calabria
Donato Calabria
ARAldo Roda
Aldo Roda
Arrigo CiceroArrigo Cicero
Arrigo Cicero
There is a direct relationship between fructose intake and serum levels of uric acid (UA), which is the final product of purine metabolism. Recent preclinical and clinical evidence suggests that chronic hyperuricemia is an independent risk factor for hypertension, metabolic syndrome, and cardiovascular disease. It is probably also an independent risk factor for chronic kidney disease, Type 2 diabetes, and cognitive decline. These relationships have been observed for high serum UA levels (>5.5 mg/dL in women and >6 mg/dL in men), but also for normal to high serum UA levels (5–6 mg/dL). In this regard, blood UA levels are much higher in industrialized countries than in the rest of the world. Xanthine-oxidase inhibitors can reduce UA and seem to minimize its negative effects on vascular health. Other dietary and pathophysiological factors are also related to UA production. However, the role of fructose-derived UA in the pathogenesis of cardiometabolic disorders has not yet been fully clarified. Here, we critically review recent research on the biochemistry of UA production, the relationship between fructose intake and UA production, and how this relationship is linked to cardiometabolic disorders.

1 August 2017 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
DCDonato Calabria
Donato Calabria
Cristiana CalicetiCristiana Caliceti
Cristiana Caliceti
MZMartina Zangheri
Martina Zangheri
Mara MirasoliMara Mirasoli
Mara Mirasoli
PSPatrizia Simoni
Patrizia Simoni
ARAldo Roda
Aldo Roda

1 April 2014 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
FSFrancesco Vieceli Dalla Sega
Francesco Vieceli Dalla Sega
LZLaura Zambonin
Laura Zambonin
DFDiana Fiorentini
Diana Fiorentini
BRBenedetta Rizzo
Benedetta Rizzo
Cristiana CalicetiCristiana Caliceti
Cristiana Caliceti
CPCecilia Prata
Cecilia Prata

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Cristiana CalicetiCristiana Caliceti
Cristiana Caliceti
PNP. Nigro
P. Nigro
PRP. Rizzo
P. Rizzo
RFRoberto Ferrari
Roberto Ferrari
Reactive oxygen species (ROS), traditionally viewed as toxic by-products that cause damage to biomolecules, now are clearly recognized as key modulators in a variety of biological processes and pathological states. The development and regulation of the cardiovascular system require orchestrated activities; Notch and Wnt/β-catenin signaling pathways are implicated in many aspects of them, including cardiomyocytes and smooth muscle cells survival, angiogenesis, progenitor cells recruitment and differentiation, arteriovenous specification, vascular cell migration, and cardiac remodelling. Several novel findings regarding the role of ROS in Notch and Wnt/β-catenin modulation prompted us to review their emerging function in the cardiovascular system during embryogenesis and postnatally.

13 May 2016 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
Cristiana CalicetiCristiana Caliceti
Cristiana Caliceti
PFPlacido Franco
Placido Franco
SSSilvia Spinozzi
Silvia Spinozzi
ARAldo Roda
Aldo Roda
Arrigo CiceroArrigo Cicero
Arrigo Cicero
Berberine is a quaternary ammonium salt from the protoberberine group of isoquinoline alkaloids found in such plants as gender Berberis. Berberine is recognised to improve glucose and lipid metabolism disorders and preliminary clinical evidences suggest the ability of berberine to reduce endothelial inflammation improving vascular health, even in patients already affected by cardiovascular diseases, suggesting a possible interesting role of berberine and its metabolites in clinical practice. However, its physicochemical properties, pharmacokinetic, and metabolism are not fully elucidated and contradictory data have been reported. This review provides a summary regarding the pharmacological and biological features of berberine, with a focus on berberine as well as their pharmacologically active metabolites and the different mechanisms underlying their activities in order to clarify the correct use of berberine supplementation, alone or in association with other nutraceuticals, for the management of metabolic disorders associated to increased cardiovascular disease risk. A particular attention has also been given to the available clinical trials assessing its short- and middle- term use tolerability, safety and efficacy in various conditions, such as dyslipidaemia, impaired fasting glucose, metabolic syndrome and type 2 diabetes.

1 February 2012 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
JOJin Oshikawa
Jin Oshikawa
SKSeok-Jo Kim
Seok-Jo Kim
EFEiji Furuta
Eiji Furuta
Cristiana CalicetiCristiana Caliceti
Cristiana Caliceti
GCGin-Fu Chen
Gin-Fu Chen
MUMasuko Ushio-Fukai
Masuko Ushio-Fukai
P66Shc, a longevity adaptor protein, is demonstrated as a key regulator of reactive oxygen species (ROS) metabolism involved in aging and cardiovascular diseases. Vascular endothelial growth factor (VEGF) stimulates endothelial cell (EC) migration and proliferation primarily through the VEGF receptor-2 (VEGFR2). We have shown that ROS derived from Rac1-dependent NADPH oxidase are involved in VEGFR2 autophosphorylation and angiogenic-related responses in ECs. However, a role of p66Shc in VEGF signaling and physiological responses in ECs is unknown. Here we show that VEGF promotes p66Shc phosphorylation at Ser36 through the JNK/ERK or PKC pathway as well as Rac1 binding to a nonphosphorylated form of p66Shc in ECs. Depletion of endogenous p66Shc with short interfering RNA inhibits VEGF-induced Rac1 activity and ROS production. Fractionation of caveolin-enriched lipid raft demonstrates that p66Shc plays a critical role in VEGFR2 phosphorylation in caveolae/lipid rafts as well as downstream p38MAP kinase activation. This in turn stimulates VEGF-induced EC migration, proliferation, and capillary-like tube formation. These studies uncover a novel role of p66Shc as a positive regulator for ROS-dependent VEGFR2 signaling linked to angiogenesis in ECs and suggest p66Shc as a potential therapeutic target for various angiogenesis-dependent diseases.